

# Jack D Sobel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12057664/publications.pdf>

Version: 2024-02-01

276  
papers

33,734  
citations

10650

74  
h-index

4414

178  
g-index

288  
all docs

288  
docs citations

288  
times ranked

22226  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis. <i>Clinical Infectious Diseases</i> , 2022, 74, 2129-2135.	2.9	12
2	Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). <i>Clinical Infectious Diseases</i> , 2022, 74, 1979-1985.	2.9	38
3	Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306). <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 412-420.	1.1	27
4	Mixed Vaginitis Due to Bacterial Vaginosis and Candidiasis. <i>Journal of Lower Genital Tract Disease</i> , 2022, 26, 68-70.	0.9	9
5	Lower Genital Tract Microbiome—A Work in Progress. <i>Journal of Lower Genital Tract Disease</i> , 2022, 26, 71-72.	0.9	0
6	Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. <i>Clinical Infectious Diseases</i> , 2022, 74, S162-S168.	2.9	25
7	Diagnosis and Management of Bacterial Vaginosis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. <i>Clinical Infectious Diseases</i> , 2022, 74, S144-S151.	2.9	16
8	Ibrexafungerp for the treatment of vulvovaginal candidiasis. <i>Drugs of Today</i> , 2022, 58, 149-158.	0.7	1
9	The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment. <i>Antibiotics</i> , 2022, 11, 500.	1.5	14
10	Vulvovaginal candidiasis: An overview of mycological, clinical, and immunological aspects. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, 48, 1546-1560.	0.6	13
11	Antimicrobial Susceptibility of Microbiota in Bacterial Vaginosis Using Fluorescence In Situ Hybridization. <i>Pathogens</i> , 2022, 11, 456.	1.2	3
12	Donald Kaye: 1931–2020, in Memoriam. <i>Clinical Infectious Diseases</i> , 2021, 72, 2244-2245.	2.9	0
13	A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis. <i>Clinical Infectious Diseases</i> , 2021, 73, e1518-e1524.	2.9	39
14	Syndromic Treatment of Women With Vulvovaginal Symptoms in the United States: A Call to Action!. <i>Clinical Infectious Diseases</i> , 2021, 72, 1544-1545.	2.9	7
15	Cell wall protein variation, break-induced replication, and subtelomere dynamics in <i>Candida glabrata</i> . <i>Molecular Microbiology</i> , 2021, 116, 260-276.	1.2	16
16	Current and emerging pharmacotherapy for recurrent bacterial vaginosis. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1593-1600.	0.9	11
17	Recurrent Bacterial Vaginosis: An Unmet Therapeutic Challenge. Experience With a Combination Pharmacotherapy Long-Term Suppressive Regimen. <i>Sexually Transmitted Diseases</i> , 2021, 48, 761-765.	0.8	14
18	Elevated COVID19 mortality risk in Detroit area hospitals among patients from census tracts with extreme socioeconomic vulnerability. <i>EClinicalMedicine</i> , 2021, 34, 100814.	3.2	9

#	ARTICLE	IF	CITATIONS
19	Vaginal Isolates of <i>Candida glabrata</i> Are Uniquely Susceptible to Ionophoric Killer Toxins Produced by <i>Saccharomyces cerevisiae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0245020.	1.4	4
20	<i>In Vitro</i> pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant <i>Candida</i> Isolates from Women with Vulvovaginal Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0056221.	1.4	11
21	Prognosis of recurrent bacterial vaginosis based on longitudinal changes in abundance of <i>Lactobacillus</i> and specific species of <i>Gardnerella</i> . <i>PLoS ONE</i> , 2021, 16, e0256445.	1.1	15
22	Protozoan-Viral-Bacterial Co-Infections Alter Galectin Levels and Associated Immunity Mediators in the Female Genital Tract. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 649940.	1.8	10
23	Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment. <i>BMC Medicine</i> , 2021, 19, 194.	2.3	38
24	Data on Safety of Intravaginal Boric Acid Use in Pregnant and Nonpregnant Women: A Narrative Review. <i>Sexually Transmitted Diseases</i> , 2021, 48, e241-e247.	0.8	5
25	Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e672-e679.	2.9	18
26	Algorithm for Managing Vulvovaginal Symptoms. , 2021, , 544-551.		0
27	Non-infectious Benign Vaginal Conditions. , 2021, , 257-265.		0
28	Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis. <i>Future Microbiology</i> , 2021, 16, 1453-1461.	1.0	42
29	Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by <i>Candida albicans</i> . <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 48-52.	0.9	28
30	Desquamative Inflammatory Vaginitis as an Extraintestinal Manifestation of Crohn's Disease. <i>Current Infectious Disease Reports</i> , 2020, 22, 1.	1.3	0
31	Diversity of the hepatitis C virus NS5B gene during HIV co-infection. <i>PLoS ONE</i> , 2020, 15, e0237162.	1.1	5
32	Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 893-900.	1.9	38
33	Use of a Novel Couples' Verification Tool in a Male Partner Treatment Study of Women With Recurrent Bacterial Vaginosis. <i>Sexually Transmitted Diseases</i> , 2020, 47, e58-e61.	0.8	4
34	Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 2297-2307.	1.1	16
35	Algorithms for Managing Vulvovaginal Symptoms—a Practical Primer. <i>Current Infectious Disease Reports</i> , 2019, 21, 40.	1.3	5
36	Prognostic Indicators of Recurrence of Bacterial Vaginosis. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	29

#	ARTICLE	IF	CITATIONS
37	Re: A systematic review of drug treatment of vulvodynia: evidence of a strong placebo effect. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 945-946.	1.1	1
38	Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Women's Health, 2019, 19, 48.	0.8	133
39	CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial. Journal of Lower Genital Tract Disease, 2019, 23, 226-229.	0.9	16
40	A Role for Yeast/Pseudohyphal Cells of <i>Candida albicans</i> in the Correlated Expression of NLRP3 Inflammasome Inducers in Women With Acute Vulvovaginal Candidiasis. Frontiers in Microbiology, 2019, 10, 2669.	1.5	14
41	Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. American Journal of Obstetrics and Gynecology, 2019, 220, 91.e1-91.e8.	0.7	67
42	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive <i>Candida</i> Infections: The ACTIVE Trial. Clinical Infectious Diseases, 2019, 68, 1981-1989.	2.9	120
43	A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2018, 66, 1928-1936.	2.9	134
44	A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered AVT-1161 in the treatment of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology, 2018, 218, 624.e1-624.e9.	0.7	68
45	Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. Journal of Lower Genital Tract Disease, 2018, 22, 382-386.	0.9	16
46	Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infectious Diseases, 2018, 18, e339-e347.	4.6	334
47	Good Clinical Practice in Diagnosis of Vulvovaginal Symptoms. JAMA Internal Medicine, 2018, 178, 1135.	2.6	0
48	Reply. American Journal of Obstetrics and Gynecology, 2017, 216, 427.	0.7	0
49	Cytokine/chemokine expression associated with Human Papillomavirus (HPV) infection in women with HIV. Journal of Medical Virology, 2017, 89, 1904-1911.	2.5	12
50	The Role of Resistance in <i>Candida</i> Infections: Epidemiology and Treatment. , 2017, , 1075-1097.		4
51	Vaginitis, Vulvitis, Cervicitis and Cutaneous Vulval Lesions. , 2017, , 483-491.e1.		6
52	<i>Candida</i> vulvovaginitis: A store with a butterfly and a show window. Mycoses, 2017, 60, 70-72.	1.8	23
53	In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against <i>Candida</i> spp. isolates from patients with vulvovaginal candidiasis. Journal of Antimicrobial Chemotherapy, 2017, 72, 1355-1358.	1.3	28
54	Antifungal Targets, Mechanisms of Action, and Resistance in <i>Candida albicans</i> . , 2017, , 429-475.		3

#	ARTICLE	IF	CITATIONS
55	Bacterial Vaginosis. , 2017, , 165-174.		2
56	Current Treatment of Bacterial Vaginosis—Limitations and Need for Innovation. <i>Journal of Infectious Diseases</i> , 2016, 214, S14-S20.	1.9	156
57	A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal <i>Candida albicans</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5858-5866.	1.4	64
58	Utilization of molecular methods to identify prognostic markers for recurrent bacterial vaginosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 231-242.	0.8	25
59	Prevalent mutator genotype identified in fungal pathogen <i>Candida glabrata</i> promotes multi-drug resistance. <i>Nature Communications</i> , 2016, 7, 11128.	5.8	227
60	Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. <i>Clinical Infectious Diseases</i> , 2016, 63, 754-762.	2.9	281
61	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, 409-417.	2.9	1,258
62	Development and Validation of a Highly Accurate Quantitative Real-Time PCR Assay for Diagnosis of Bacterial Vaginosis. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1017-1024.	1.8	74
63	Experimental Models of Vaginal Candidiasis and Their Relevance to Human Candidiasis. <i>Infection and Immunity</i> , 2016, 84, 1255-1261.	1.0	42
64	Fungal Infections. <i>Infectious Disease Clinics of North America</i> , 2016, 30, xiii-xiv.	1.9	3
65	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, e1-e50.	2.9	2,489
66	Identification of intrinsically metronidazole-resistant clades of <i>Gardnerella vaginalis</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 1-3.	0.8	57
67	Recurrent vulvovaginal candidiasis. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 15-21.	0.7	373
68	A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis. <i>Sexually Transmitted Diseases</i> , 2015, 42, 376-381.	0.8	22
69	Editorial Commentary: Vaginal Biofilm: Much Ado About Nothing, or a New Therapeutic Challenge?. <i>Clinical Infectious Diseases</i> , 2015, 61, 607-608.	2.9	25
70	CX <sub>3</sub> CR1 Is Dispensable for Control of Mucosal <i>Candida albicans</i> Infections in Mice and Humans. <i>Infection and Immunity</i> , 2015, 83, 958-965.	1.0	31
71	Metronidazole for the treatment of vaginal infections. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1109-1115.	0.9	52
72	A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic <i>Trichomonas vaginalis</i> Infections. <i>Clinical Infectious Diseases</i> , 2015, 61, S837-S848.	2.9	121

#	ARTICLE	IF	CITATIONS
73	Dense Genotyping of Immune-Related Loci Identifies Variants Associated with Clearance of HPV among HIV-Positive Women in the HIV Epidemiology Research Study (HERS). <i>PLoS ONE</i> , 2014, 9, e99109.	1.1	14
74	GB Virus C (GBV-C) Infection in Hepatitis C Virus (HCV) Seropositive Women with or at Risk for HIV Infection. <i>PLoS ONE</i> , 2014, 9, e114467.	1.1	8
75	Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. <i>Current Medical Research and Opinion</i> , 2014, 30, 1109-1119.	0.9	124
76	Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. <i>Frontiers in Microbiology</i> , 2014, 5, 483.	1.5	66
77	Utilization of PCR to Characterize Vaginal Flora in a Longitudinal Study of Recurrent Bacterial Vaginosis. <i>Open Forum Infectious Diseases</i> , 2014, 1, S371-S372.	0.4	0
78	High-Dose Vaginal Maintenance Metronidazole for Recurrent Bacterial Vaginosis. <i>Sexually Transmitted Diseases</i> , 2014, 41, 290-291.	0.8	20
79	High-Dose Vaginal Metronidazole for Recurrent Bacterial Vaginosis—A Pilot Study. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, 156-161.	0.9	11
80	MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting. <i>Clinical Infectious Diseases</i> , 2014, 58, 1219-1226.	2.9	142
81	Multiplex quantitative polymerase chain reaction assay for the identification and quantitation of major vaginal lactobacilli. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 321-327.	0.8	29
82	Genital candidiasis. <i>Medicine</i> , 2014, 42, 364-368.	0.2	17
83	Are Echinocandins Better Than Azoles for Invasive Candidiasis?. <i>Current Fungal Infection Reports</i> , 2013, 7, 79-82.	0.9	2
84	Mixed Vaginitis—More Than Coinfection and With Therapeutic Implications. <i>Current Infectious Disease Reports</i> , 2013, 15, 104-108.	1.3	77
85	Genital Mycotic Infections in Patients With Diabetes. <i>Postgraduate Medicine</i> , 2013, 125, 33-46.	0.9	70
86	Novel PCR-Based Methods Enhance Characterization of Vaginal Microbiota in a Bacterial Vaginosis Patient before and after Treatment. <i>Applied and Environmental Microbiology</i> , 2013, 79, 4181-4185.	1.4	20
87	Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, 340-345.	0.9	201
88	Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis. <i>Patient Preference and Adherence</i> , 2013, 8, 31.	0.8	31
89	Longitudinal Analysis of Vaginal Microbiome Dynamics in Women with Recurrent Bacterial Vaginosis: Recognition of the Conversion Process. <i>PLoS ONE</i> , 2013, 8, e82599.	1.1	53
90	Genital Malodor in Women. <i>Journal of Lower Genital Tract Disease</i> , 2012, 16, 49-55.	0.9	6

#	ARTICLE	IF	CITATIONS
91	Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2012, 54, 1110-1122.	2.9	649
92	Effect of pH on <i>In Vitro</i> Susceptibility of <i>Candida glabrata</i> and <i>Candida albicans</i> to 11 Antifungal Agents and Implications for Clinical Use. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1403-1406.	1.4	91
93	Fluconazole-Resistant <i>Candida albicans</i> Vulvovaginitis. <i>Obstetrics and Gynecology</i> , 2012, 120, 1407-1414.	1.2	151
94	Miconazole Mucoadhesive Tablets: A Novel Delivery System. <i>Clinical Infectious Diseases</i> , 2012, 54, 1480-1484.	2.9	31
95	Diagnosing vaginal infections through measurement of biogenic amines by ion mobility spectrometry. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 163, 81-84.	0.5	31
96	A case of <i>Conidiobolus coronatus</i> in the vagina. <i>Medical Mycology</i> , 2011, 49, 427-429.	0.3	7
97	<i>Candida</i> Urinary Tract Infections—Diagnosis. <i>Clinical Infectious Diseases</i> , 2011, 52, S452-S456.	2.9	123
98	<i>Candida glabrata</i> complicating in vitro pregnancy: successful management of subsequent pregnancy. <i>Fertility and Sterility</i> , 2011, 95, 803.e1-803.e2.	0.5	18
99	Douching for Perceived Vaginal Odor With No Infectious Cause of Vaginitis. <i>Journal of Lower Genital Tract Disease</i> , 2011, 15, 128-133.	0.9	5
100	Prognosis and Treatment of Desquamative Inflammatory Vaginitis. <i>Obstetrics and Gynecology</i> , 2011, 117, 850-855.	1.2	60
101	Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. <i>Mycoses</i> , 2011, 54, 46-51.	1.8	98
102	Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 177-190.	0.7	152
103	A Case of High-Level Metronidazole-Resistant Trichomoniasis in Pregnancy Successfully Treated. <i>Journal of Lower Genital Tract Disease</i> , 2011, 15, 248-249.	0.9	4
104	The Association Between <i>Trichomonas</i> Infection and Incarceration in HIV-Seropositive and At-Risk HIV-Seronegative Women. <i>Sexually Transmitted Diseases</i> , 2011, 38, 1094-1100.	0.8	20
105	<i>Candida</i> Urinary Tract Infection: Pathogenesis. <i>Clinical Infectious Diseases</i> , 2011, 52, S437-S451.	2.9	113
106	<i>Candida</i> Urinary Tract Infections—Epidemiology. <i>Clinical Infectious Diseases</i> , 2011, 52, S433-S436.	2.9	178
107	<i>Candida</i> Urinary Tract Infections—Treatment. <i>Clinical Infectious Diseases</i> , 2011, 52, S457-S466.	2.9	157
108	Ocular Manifestations of Candidemia. <i>Clinical Infectious Diseases</i> , 2011, 53, 262-268.	2.9	171

#	ARTICLE	IF	CITATIONS
109	Association between Semen Exposure and Incident Bacterial Vaginosis. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2011, 2011, 1-10.	0.4	28
110	Accuracy of Clinical Diagnosis of Bacterial Vaginosis by Human Immunodeficiency Virus Infection Status. <i>Sexually Transmitted Diseases</i> , 2011, 38, 270-274.	0.8	12
111	Septic Shock Due to Candidemia: Outcomes and Predictors of Shock Development. <i>Journal of Clinical Medicine Research</i> , 2011, 3, 65-71.	0.6	32
112	Genital Candidiasis. , 2011, , 613-624.		1
113	<i>Candida kefyr</i> Endocarditis in a Patient With Hypertrophic Obstructive Cardiomyopathy. <i>American Journal of the Medical Sciences</i> , 2010, 339, 188-189.	0.4	13
114	Dynamics of the Vaginal Ecosystemâ€™ Hormonal Influences. <i>Infectious Diseases: Research and Treatment</i> , 2010, 3, IDRT.S3903.	0.7	37
115	Yeast Infections of the Lower Urinary Tract: Recommendations for Diagnosis and Treatment. <i>Current Fungal Infection Reports</i> , 2010, 4, 175-178.	0.9	3
116	Vulvovaginal Candidiasis Caused by Non-albicans <i>Candida</i> Species: New Insights. <i>Current Infectious Disease Reports</i> , 2010, 12, 465-470.	1.3	94
117	Genital candidiasis. <i>Medicine</i> , 2010, 38, 286-290.	0.2	7
118	Chronic Pain of the Vulva without Dermatologic Manifestations: Distinguishing among a Spectrum of clinical Disorders. <i>Clinical Medicine Insights Women's Health</i> , 2010, 3, CMWH.S3950.	0.6	2
119	Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDSâ€™Associated Acute Cryptococcal Meningitis: A Randomized, Doubleâ€™Blind Clinical Trial of Efficacy and Safety. <i>Clinical Infectious Diseases</i> , 2010, 51, 225-232.	2.9	150
120	Diagnostic techniques for bacterial vaginosis and vulvovaginal candidiasis â€™ requirement for a simple differential test. <i>Expert Opinion on Medical Diagnostics</i> , 2010, 4, 333-341.	1.6	8
121	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2010, 50, 291-322.	2.9	2,195
122	Vaginitis, vulvitis, cervicitis and cutaneous vulval lesions. , 2010, , 542-550.		1
123	The Vaginal Microbiota in Menopause. , 2010, , 883-893.		2
124	Guidelines for the treatment of bacterial vaginosis: focus on tinidazole. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 485.	0.9	21
125	Fungal infections of the genitourinary tract. , 2009, , 547-559.		1
126	A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIVâ€™Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2009, 48, 1775-1783.	2.9	141



#	ARTICLE	IF	CITATIONS
127	Use of the VS-Sense Swab in Diagnosing Vulvovaginitis. <i>Journal of Women's Health</i> , 2009, 18, 1467-1470.	1.5	6
128	Boric Acid Addition to Suppressive Antimicrobial Therapy for Recurrent Bacterial Vaginosis. <i>Sexually Transmitted Diseases</i> , 2009, 36, 732-734.	0.8	87
129	Cryptococcal Immune Reconstitution Inflammatory Syndrome after Antiretroviral Therapy in AIDS Patients with Cryptococcal Meningitis: A Prospective Multicenter Study. <i>Clinical Infectious Diseases</i> , 2009, 49, 931-934.	2.9	103
130	Antibiotic consideration in bacterial vaginosis. <i>Current Infectious Disease Reports</i> , 2009, 11, 471-475.	1.3	13
131	Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2009, 48, 503-535.	2.9	2,644
132	Reduced fluconazole susceptibility of <i>Candida albicans</i> isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 354-356.	0.8	48
133	Antifungal Targets, Mechanisms of Action, and Resistance in <i>Candida albicans</i> . , 2009, , 347-407.		5
134	Fungal endocarditis. <i>Current Infectious Disease Reports</i> , 2008, 10, 275-279.	1.3	15
135	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008, 46, 1813-1821.	2.9	4,375
136	Effect of Antibiotics on Vulvovaginal Candidiasis: A MetroNet Study. <i>Journal of the American Board of Family Medicine</i> , 2008, 21, 261-268.	0.8	76
137	Empirical Fluconazole versus Placebo for Intensive Care Unit Patients. <i>Annals of Internal Medicine</i> , 2008, 149, 83.	2.0	191
138			

#	ARTICLE	IF	CITATIONS
145	Bacterial vaginosis: Culture- and PCR-based characterizations of a complex polymicrobial disease's pathobiology. <i>Current Infectious Disease Reports</i> , 2007, 9, 485-500.	1.3	34
146	The emergence of non-albicans <i>Candida</i> species as causes of invasive candidiasis and candidemia. <i>Current Fungal Infection Reports</i> , 2007, 1, 42-48.	0.9	6
147	Failure of Nitazoxanide to Cure Trichomoniasis in Three Women. <i>Sexually Transmitted Diseases</i> , 2007, 34, 813-814.	0.8	20
148	Progress in antifungal therapy: Echinocandins versus azoles. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 221-226.	0.5	1
149	Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, 1283-1289.	0.7	249
150	The VI-SENSE™ vaginal discharge self-test to facilitate management of vaginal symptoms. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 195, 1351-1356.	0.7	18
151	The emergence of non-albicans <i>Candida</i> species as causes of invasive candidiasis and candidemia. <i>Current Infectious Disease Reports</i> , 2006, 8, 427-433.	1.3	78
152	Management of recurrent vulvovaginal candidiasis: Unresolved issues. <i>Current Infectious Disease Reports</i> , 2006, 8, 481-486.	1.3	27
153	Design of Clinical Trials of Empiric Antifungal Therapy in Patients with Persistent Febrile Neutropenia: Considerations and Critiques. <i>Pharmacotherapy</i> , 2006, 26, 47S-54S.	1.2	7
154	Antifungal Bladder Irrigation. <i>Infectious Diseases in Clinical Practice</i> , 2006, 14, 125-126.	0.1	4
155	Reviews Of Anti-Infective Agents: Anidulafungin: A Novel Echinocandin. <i>Clinical Infectious Diseases</i> , 2006, 43, 215-222.	2.9	176
156	advances in diagnosing vaginitis: Development of a new algorithm. <i>Current Infectious Disease Reports</i> , 2005, 7, 458-462.	1.3	18
157	A Randomized Study of the Use of Fluconazole in Continuous versus Episodic Therapy in Patients with Advanced HIV Infection and a History of Oropharyngeal Candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. <i>Clinical Infectious Diseases</i> , 2005, 41, 1473-1480.	2.9	72
158	Genital candidiasis. <i>Medicine</i> , 2005, 33, 62-65.	0.2	13
159	What's New in Bacterial Vaginosis and Trichomoniasis?. <i>Infectious Disease Clinics of North America</i> , 2005, 19, 387-406.	1.9	93
160	Emerging azole antifungals. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 21-33.	1.0	50
161	Combination Therapy for Invasive Mycoses: Evaluation of Past Clinical Trial Designs. <i>Clinical Infectious Diseases</i> , 2004, 39, S224-S227.	2.9	19
162	Fungicidal Activity of Fluconazole against <i>Candida albicans</i> in a Synthetic Vagina-Simulative Medium. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 161-167.	1.4	57

#	ARTICLE	IF	CITATIONS
163	Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: Results of a prospective cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 644-653.	0.7	77
164	Shuttle vectors for <i>Candida albicans</i> : control of plasmid copy number and elevated expression of cloned genes. <i>Current Genetics</i> , 2004, 45, 390-398.	0.8	23
165	<i>Candida</i> vulvovaginitis in pregnancy. <i>Current Infectious Disease Reports</i> , 2004, 6, 445-449.	1.3	16
166	Guidelines for Treatment of Candidiasis. <i>Clinical Infectious Diseases</i> , 2004, 38, 161-189.	2.9	1,371
167	Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis. <i>New England Journal of Medicine</i> , 2004, 351, 876-883.	13.9	408
168	Fluconazole for the treatment of candidiasis: 15 years experience. <i>Expert Review of Anti-Infective Therapy</i> , 2004, 2, 357-366.	2.0	71
169	Current trends and challenges in candidiasis. <i>Oncology</i> , 2004, 18, 7-8.	0.4	1
170	Estrogen replacement therapy to prevent recurrent urinary tract infection in postmenopausal women. <i>Current Infectious Disease Reports</i> , 2003, 5, 479-480.	1.3	2
171	Antibiotic-associated vulvovaginal candidiasis. <i>Current Infectious Disease Reports</i> , 2003, 5, 481-487.	1.3	18
172	Erosive vulvovaginitis. <i>Current Infectious Disease Reports</i> , 2003, 5, 494-498.	1.3	2
173	Treatment of vaginitis caused by <i>Candida glabrata</i> : use of topical boric acid and flucytosine. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 189, 1297-1300.	0.7	160
174	Vulvovaginal candidiasis. <i>Obstetrics and Gynecology Clinics of North America</i> , 2003, 30, 671-684.	0.7	39
175	Management of Patients with Recurrent Vulvovaginal Candidiasis. <i>Drugs</i> , 2003, 63, 1059-1066.	4.9	60
176	CAN-296-P is effective against cutaneous candidiasis in guinea pigs. <i>International Journal of Antimicrobial Agents</i> , 2003, 22, 168-171.	1.1	6
177	Longitudinal Study of Mucosal <i>Candida</i> Species Colonization and Candidiasis among Human Immunodeficiency Virus (HIV)â€“Seropositive and Atâ€“Risk HIVâ€“Seronegative Women. <i>Journal of Infectious Diseases</i> , 2003, 188, 118-127.	1.9	83
178	Antifungal drugs in pregnancy: a review. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 475-483.	1.0	80
179	Incident and persistent vulvovaginal candidiasis among human immunodeficiency virusâ€“infected women: Risk factors and severity. <i>Obstetrics and Gynecology</i> , 2003, 101, 548-556.	1.2	46
180	Incident and Persistent Vulvovaginal Candidiasis Among Human Immunodeficiency Virusâ€“Infected Women. <i>Obstetrics and Gynecology</i> , 2003, 101, 548-556.	1.2	31

#	ARTICLE	IF	CITATIONS
181	Vulvovaginal Trichosporonosis. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2003, 11, 131-133.	0.4	9
182	Vulvovaginal candidiasis: a comparison of HIV-positive and -negative women. <i>International Journal of STD and AIDS</i> , 2002, 13, 358-362.	0.5	28
183	Uropathogenic <i>Escherichia coli</i> Are More Likely than Commensal <i>E. coli</i> to Be Shared between Heterosexual Sex Partners. <i>American Journal of Epidemiology</i> , 2002, 156, 1133-1140.	1.6	96
184	Over-the-Counter Antifungal Drug Misuse Associated With Patient-Diagnosed Vulvovaginal Candidiasis. <i>Obstetrics and Gynecology</i> , 2002, 99, 419-425.	1.2	7
185	Vaginitis Due to <i>Candida krusei</i> : Epidemiology, Clinical Aspects, and Therapy. <i>Clinical Infectious Diseases</i> , 2002, 35, 1066-1070.	2.9	91
186	Treatment of vaginal <i>Candida</i> infections. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1059-1065.	0.9	43
187	Oral and vaginal antifungal treatments are similarly effective for vulvovaginal candidiasis – meta-analysis. <i>Evidence-Based Obstetrics and Gynecology</i> , 2002, 4, 158-159.	0.3	0
188	Desquamative Inflammatory Vaginitis An Exploratory Case-Control Study. <i>Annals of Epidemiology</i> , 2002, 12, 346-352.	0.9	27
189	Mucosal candidiasis. <i>Infectious Disease Clinics of North America</i> , 2002, 16, 793-820.	1.9	93
190	Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. <i>Obstetrics and Gynecology</i> , 2002, 99, 419-425.	1.2	160
191	Steroid therapy of vulvovaginal lichen planus. <i>Current Infectious Disease Reports</i> , 2002, 4, 507-508.	1.3	6
192	Pathogenesis of recurrent vulvovaginal candidiasis. <i>Current Infectious Disease Reports</i> , 2002, 4, 514-519.	1.3	49
193	Prevalence and risk factors for vaginal <i>Candida</i> colonization in women with type 1 and type 2 diabetes. <i>BMC Infectious Diseases</i> , 2002, 2, 1.	1.3	174
194	Urinary tract infection among women aged 40 to 65. <i>Journal of Clinical Epidemiology</i> , 2001, 54, 710-718.	2.4	74
195	Evolution of Antifungal Susceptibility among <i>Candida</i> Species Isolates Recovered from Human Immunodeficiency Virus-Infected Women Receiving Fluconazole Prophylaxis. <i>Clinical Infectious Diseases</i> , 2001, 33, 1069-1075.	2.9	54
196	Vaginal Mucormycosis: A Case Report. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2001, 9, 117-118.	0.4	14
197	Alternative treatment modalities for prevention of urinary tract infection in women: Lactobacilli or cranberry juice?. <i>Current Infectious Disease Reports</i> , 2001, 3, 527-528.	1.3	0
198	Antimicrobial resistance in vulvovaginitis. <i>Current Infectious Disease Reports</i> , 2001, 3, 546-549.	1.3	5

#	ARTICLE	IF	CITATIONS
199	Candida glabrata: an important fungal pathogen for the 21st century. Clinical Microbiology Newsletter, 2001, 23, 171-176.	0.4	3
200	Prophylactic Antifungal Therapy in the Intensive Care Unit. Clinical Infectious Diseases, 2001, 32, 1191-1200.	2.9	168
201	The Evolution of Candida Species and Fluconazole Susceptibility among Oral and Vaginal Isolates Recovered from Human Immunodeficiency Virus (HIV) Seropositive and At-Risk HIV Seronegative Women. Journal of Infectious Diseases, 2001, 183, 286-293.	1.9	75
202	Genital Candidosis. Medicine, 2001, 29, 67-73.	0.2	0
203	Nontrichomonal purulent vaginitis: Clinical approach. Current Infectious Disease Reports, 2000, 2, 501-505.	1.3	11
204	Management of infections caused by Candida glabrata. Current Infectious Disease Reports, 2000, 2, 424-428.	1.3	12
205	Candida vaginitis. Sexually Transmitted Diseases, 2000, 27, 230-235.	0.8	133
206	Practice Guidelines for the Treatment of Fungal Infections. Clinical Infectious Diseases, 2000, 30, 652-652.	2.9	70
207	Urinary Tract Infection. Annals of Epidemiology, 2000, 10, 509-515.	0.9	828
208	Gynecologic Infections in Human Immunodeficiency Virus-Infected Women. Clinical Infectious Diseases, 2000, 31, 1225-1233.	2.9	61
209	Use of Antifungal Drugs in Pregnancy. Drug Safety, 2000, 23, 77-85.	1.4	48
210	Bacterial Vaginosis. Annual Review of Medicine, 2000, 51, 349-356.	5.0	251
211	<i>Candida glabrata</i> : Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to <i>C. albicans</i> . Clinical Microbiology Reviews, 1999, 12, 80-96.	5.7	819
212	High-Frequency, In Vitro Reversible Switching of <i>Candida lusitanae</i> Clinical Isolates from Amphotericin B Susceptibility to Resistance. Antimicrobial Agents and Chemotherapy, 1999, 43, 836-845.	1.4	81
213	Involvement of calcium inhibitable binding to the cell wall in the fungicidal activity of CAN-296. Journal of Antimicrobial Chemotherapy, 1999, 44, 217-222.	1.3	7
214	Mass or syndromic treatment of sexually transmitted infections. Current Infectious Disease Reports, 1999, 1, 365-366.	1.3	0
215	Is there a protective role for vaginal flora?. Current Infectious Disease Reports, 1999, 1, 379-383.	1.3	82
216	Metronidazole-Resistant Vaginal Trichomoniasis – An Emerging Problem. New England Journal of Medicine, 1999, 341, 292-293.	13.9	97

#	ARTICLE	IF	CITATIONS
217	Limitations of antifungal agents in the treatment of <i>Candida</i> vaginitis: future challenges. <i>Drug Resistance Updates</i> , 1999, 2, 148-152.	6.5	13
218	Comparative in Vitro Activity of Antiseptics and Disinfectants Versus Clinical Isolates of <i>Candida</i> Species. <i>Infection Control and Hospital Epidemiology</i> , 1999, 20, 676-684.	1.0	18
219	Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. <i>American Journal of Obstetrics and Gynecology</i> , 1998, 178, 203-211.	0.7	540
220	Frequency and Response to Vaginal Symptoms among White and African American Women: Results of a Random Digit Dialing Survey. <i>Journal of Women's Health</i> , 1998, 7, 1167-1174.	0.9	75
221	VULVOVAGINITIS. <i>Dermatologic Clinics</i> , 1998, 16, 763-768.	1.0	22
222	Mucosal Candidal Colonization and Candidiasis in Women with or at Risk for Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 1998, 27, 1161-1167.	2.9	92
223	Difficult to Treat Trichomoniasis: Results with Paromomycin Cream. <i>Clinical Infectious Diseases</i> , 1998, 26, 986-988.	2.9	69
224	Nosocomial <i>Candida glabrata</i> Colonization: an Epidemiologic Study. <i>Journal of Clinical Microbiology</i> , 1998, 36, 421-426.	1.8	112
225	Stable Phenotypic Resistance of <i>Candida</i> Species to Amphotericin B Conferred by Preexposure to Subinhibitory Levels of Azoles. <i>Journal of Clinical Microbiology</i> , 1998, 36, 2690-2695.	1.8	39
226	Development and verification of fingerprinting probes for <i>Candida glabrata</i> . <i>Microbiology (United Kingdom)</i> , 1997, 141, 107-114.	0.7	70
227	Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1997, 337, 15-21.	13.9	745
228	In Vitro Antifungal Activity of CAN-296: A Naturally Occurring Complex Carbohydrate. <i>Journal of Antibiotics</i> , 1997, 50, 937-943.	1.0	7
229	Vaginitis. <i>New England Journal of Medicine</i> , 1997, 337, 1896-1903.	13.9	450
230	PATHOGENESIS OF URINARY TRACT INFECTION. <i>Infectious Disease Clinics of North America</i> , 1997, 11, 531-549.	1.9	85
231	Recurrent vulvovaginal candidiasis associated with long-term tamoxifen treatment in postmenopausal women. <i>Obstetrics and Gynecology</i> , 1996, 88, 704-706.	1.2	20
232	Validity of the Vaginal Gram Stain for the Diagnosis of Bacterial Vaginosis. <i>Obstetrics and Gynecology</i> , 1996, 88, 573-576.	1.2	212
233	Aphthous vaginal ulceration in two women with acquired immunodeficiency syndrome. <i>American Journal of Obstetrics and Gynecology</i> , 1996, 174, 1660-1663.	0.7	14
234	Comparative study of intravaginal metronidazole and triple-sulfa therapy for bacterial vaginosis. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 1996, 4, 66-70.	0.4	4

#	ARTICLE	IF	CITATIONS
235	Trichomoniasis as seen in a chronic vaginitis clinic. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 1996, 4, 77-84.	0.4	4
236	Candida vulvovaginitis. <i>Seminars in Dermatology</i> , 1996, 15, 17-28.	0.6	16
237	Comparative study of intravaginal metronidazole and triple-sulfa therapy for bacterial vaginosis. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 1996, 4, 66-70.	0.4	1
238	Treatment Options for Vulvovaginal Candidiasis, 1993. <i>Clinical Infectious Diseases</i> , 1995, 20, S80-S90.	2.9	55
239	vaginitis: Transmission from yeast used in baking. <i>Obstetrics and Gynecology</i> , 1995, 86, 326-329.	1.2	37
240	Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 172, 1263-1268.	0.7	135
241	FUNGAL INFECTIONS IN DIABETES. <i>Infectious Disease Clinics of North America</i> , 1995, 9, 97-116.	1.9	58
242	Candida Vaginitis. <i>Infectious Diseases in Clinical Practice</i> , 1994, 3, 334-339.	0.1	5
243	Controversial aspects in the management of vulvovaginal candidiasis. <i>Journal of the American Academy of Dermatology</i> , 1994, 31, S10-S13.	0.6	23
244	Desquamative inflammatory vaginitis: A new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. <i>American Journal of Obstetrics and Gynecology</i> , 1994, 171, 1215-1220.	0.7	129
245	The role of cell-mediated immunity in candidiasis. <i>Trends in Microbiology</i> , 1994, 2, 202-206.	3.5	102
246	Management of Vaginosis. <i>Drug Investigation</i> , 1994, 8, 26-34.	0.6	2
247	Nosocomial acquisition of Candida parapsilosis: An epidemiologic study. <i>American Journal of Medicine</i> , 1993, 94, 577-582.	0.6	124
248	Nosocomial Acquisition of Candida albicans: An Epidemiologic Study. <i>Journal of Infectious Diseases</i> , 1993, 168, 195-201.	1.9	165
249	Candidal Vulvovaginitis. <i>Clinical Obstetrics and Gynecology</i> , 1993, 36, 153-165.	0.6	143
250	Women and AIDS. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1993, 33, 341-350.	0.4	8
251	Vulvovaginitis. <i>Dermatologic Clinics</i> , 1992, 10, 339-359.	1.0	27
252	Urinary Excretion of Tamm-Horsfall Protein in Elderly Women. <i>Journal of Urology</i> , 1991, 146, 806-808.	0.2	21

#	ARTICLE	IF	CITATIONS
253	A New Slide Latex Agglutination Test for the Diagnosis of Acute Candida Vaginitis. American Journal of Clinical Pathology, 1990, 94, 323-325.	0.4	10
254	Vulvovaginal Candidiasis Complicating Recurrent Bacterial Vaginosis. Sexually Transmitted Diseases, 1990, 17, 51-53.	0.8	29
255	Emerging Role of Lactobacilli in the Control and Maintenance of the Vaginal Bacterial Microflora. Clinical Infectious Diseases, 1990, 12, 856-872.	2.9	448
256	Individualizing treatment of vaginal candidiasis. Journal of the American Academy of Dermatology, 1990, 23, 572-576.	0.6	12
257	Therapeutic Considerations in Fungal Vaginitis. Handbook of Experimental Pharmacology, 1990, , 365-383.	0.9	3
258	Vaginitis in Adult Women. Obstetrics and Gynecology Clinics of North America, 1990, 17, 851-879.	0.7	16
259	Bacterial Vaginosis-An Ecologic Mystery. Annals of Internal Medicine, 1989, 111, 551.	2.0	40
260	A New ELISA Method for the Rapid Quantification of Tamm-Horsfall Protein in Urine. American Journal of Clinical Pathology, 1989, 92, 199-205.	0.4	16
261	Pathogenesis of Candida Vulvovaginitis. Current Topics in Medical Mycology, 1989, 3, 86-108.	0.8	34
262	Pathogenesis and Epidemiology of Vulvovaginal Candidiasis. Annals of the New York Academy of Sciences, 1988, 544, 547-557.	1.8	179
263	Pathogenesis of Urinary Tract Infections Host Defenses. Infectious Disease Clinics of North America, 1987, 1, 751-772.	1.9	32
264	Zinc status in women with recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology, 1986, 155, 1082-1085.	0.7	23
265	Recurrent Vulvovaginal Candidiasis. New England Journal of Medicine, 1986, 315, 1455-1458.	13.9	202
266	Recurrent Vulvovaginal Candidiasis. Obstetrics and Gynecology, 1986, 67, 810-812.	1.2	23
267	Experimental chronic vaginal candidosis in rats. Medical Mycology, 1985, 23, 199-206.	0.3	65
268	Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology, 1985, 152, 924-935.	0.7	300
269	Pathogenesis of Bacteriuria in Elderly Women: The Role of Escherichia Coli Adherence to Vaginal Epithelial Cells. Journal of Gerontology, 1984, 39, 682-685.	2.0	20
270	Vulvovaginal Candidiasis—What We Do and Do Not Know. Annals of Internal Medicine, 1984, 101, 390.	2.0	46



#	ARTICLE	IF	CITATIONS
271	Candiduria. , 0, , 457-460.		0
272	Non- <i>albicans Candida</i> Infections. , 0, , 393-411.		0
273	Candiduria. , 0, , 430-433.		0
274	Mucosal Candidiasis. , 0, , 417-427.		4
275	Determining Susceptibility in <i>Candida</i> Vaginal Isolates. Antimicrobial Agents and Chemotherapy, 0, , .	1.4	4
276	Desquamative Inflammatory Vaginitis as an Expression of Systemic Lupus Erythematosus. Journal of Lower Genital Tract Disease, 0, Publish Ahead of Print, .	0.9	0